Diagnosis and management of extranodal NK/T cell lymphoma nasal type

References

• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol. 2011;11(10):645–657.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16(2):112–123.
   PubMed Web of Science ®Google Scholar
• Montaldo E, Vacca P, Moretta L, et al. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014;26(2):107–113.
   PubMed Web of Science ®Google Scholar
• Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201–214.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ooi GC, Shek TW, et al. Lethal midline granuloma revisited: nasal T/Natural-killer cell lymphoma. J Clin Oncol. 1999;17(4):1322–1325.
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186–2194.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84(5):1361–1392.
   PubMed Web of Science ®Google Scholar
• Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+. Blood. 1996;87(2):839–841.
   PubMed Web of Science ®Google Scholar
• Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36(4):481–499.
   PubMed Web of Science ®Google Scholar
• Hong M, Lee T, Young Kang S, et al. Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior. Mod Pathol. 2016;29(5):430–443.
   PubMed Web of Science ®Google Scholar
• Chan JK, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al. editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 285–288.
   Google Scholar
• Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol. 1997;98(4):922–926.
   PubMed Web of Science ®Google Scholar
• Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155(5):1419–1425.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000;157(6):1803–1809.
   PubMed Web of Science ®Google Scholar
• Küçük C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA. 2011;108(50):20119–20124.
   PubMed Web of Science ®Google Scholar
• Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118(12):3195–3204.
   PubMed Web of Science ®Google Scholar
• Küçük C, Hu X, Iqbal J, et al. HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. Am J Pathol. 2013;182(1):49–55.
   PubMed Web of Science ®Google Scholar
• Chen YW, Guo T, Shen L, et al. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. Blood. 2015;125(10):1589–1600.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Weisenburger DD, Chowdhury A, et al. International peripheral T-cell lymphoma project. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase a inhibitor in vitro. Leukemia. 2011;25(2):348–358.
   PubMed Web of Science ®Google Scholar
• Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011;223(4):496–510.
   PubMed Web of Science ®Google Scholar
• Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591–597.
   PubMed Web of Science ®Google Scholar
• Küçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 2015;6:6025.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015;47(9):1061–1066.
   PubMed Web of Science ®Google Scholar
• Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764–17776.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Wong KF, et al. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol. 2002;160(1):59–66.
   PubMed Web of Science ®Google Scholar
• Küçük C, Hu X, Jiang B, et al. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 2015;21(7):1699–1711.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Khong PL. Central palatal perforation in nasal natural killer cell lymphoma. Br J Haematol. 2011;152(1):2.
   PubMedGoogle Scholar
• Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97(4):821–829.
   PubMed Web of Science ®Google Scholar
• Takata K, Hong ME, Sitthinamsuwan P, et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia. Am J Surg Pathol. 2015;39(1):1–12.
   PubMed Web of Science ®Google Scholar
• Chim CS, Au WY, Shek TW, et al. Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer. 2001;91(3):525–533.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Jung HA, Chuang SS, et al.; Asia Lymphoma Study Group. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group. J Hematol Oncol. 2013;6:86.
   PubMed Web of Science ®Google Scholar
• Au WY, Chan AC, Kwong YL. Scrotal skin ulcer in a patient with a previous tonsillectomy because of natural killer cell lymphoma. Am J Dermatopathol. 1998;20(6):582–585.
   PubMed Web of Science ®Google Scholar
• Chim CS, Au WY, Poon C, et al. Primary natural killer cell lymphoma of skeletal muscle. Histopathology. 2002;41(4):371–374.
   PubMed Web of Science ®Google Scholar
• Chim CS, Choy C, Liang R, et al. Isolated uterine relapse of nasal T/Nk cell lymphoma. Leuk Lymphoma. 1999;34(5–6):629–632.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma ES, Loong F, et al. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement. J Clin Pathol. 2005;58(4):443–445.
   PubMed Web of Science ®Google Scholar
• Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35(8):571–575.
   PubMed Web of Science ®Google Scholar
• Tse E, Leung R, Khong PL, et al. Non-nasal natural killer cell lymphoma: not non-nasal after all. Ann Hematol. 2009;88(2):185–187.
   PubMed Web of Science ®Google Scholar
• Chan JK, Jaffe ES, Ralfkiaer E, et al. Aggresssive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al. editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 276–277.
   Google Scholar
• Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17(2):539–554.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. Practical management of natural killer/T-cell lymphoma. Curr Opin Oncol. 2012;24(5):480–486.
   PubMed Web of Science ®Google Scholar
• Ooi GC, Chim CS, Liang R, et al. Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol. 2000;174(4):1141–1145.
   PubMed Web of Science ®Google Scholar
• Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87(8):613–621.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–249.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–2017.
   PubMed Web of Science ®Google Scholar
• Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol. 2010;3(5):593–602.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126(12):1424–1432.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. Nasal NK/T-cell lymphoma: RT, CT, or both. Blood. 2015;126(12):1400–1401.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al.; GELA and GOELAMS intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–1839.
   PubMed Web of Science ®Google Scholar
• Dong LH, Zhang LJ, Wang WJ, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2016;57(7):1600–1606.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348–355.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long-term follow-up. Oncol Lett. 2015;10(2):1036–1040.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim TM, Kim KH, et al. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Ann Hematol. 2015;94(3):437–444.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of “sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118(13):3294–3301.
   PubMed Web of Science ®Google Scholar
• Ding H, Chang J, Liu LG, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. Int J Hematol. 2015;102(2):181–187.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–2980.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93(11):1895–1901.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594–5600.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30(32):4044–4046.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27(35):6027–6032.
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12(3):349–352.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78(2):163–167.
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860–868.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang M, Xie L, et al. Five-year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer Med. 2016;5(1):33–40.
   PubMed Web of Science ®Google Scholar
• Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drugs. 2013;31(2):469–472.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–221.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006 Feb 1;24(4):612–618.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Pang AW, Leung AY, et al. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865–870.
   PubMed Web of Science ®Google Scholar
• Khong PL, Huang B, Lee EY, et al. Midtreatment 1⁸F-FDG PET/CT scan for early response assessment of SMILE therapy in natural Killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med. 2014;55(6):911–916.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Choi JY, Hyun SH, et al.; Asia Lymphoma Study Group. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2(2):e66–74.
   PubMed Web of Science ®Google Scholar
• Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003;14(11):1673–1676.
   PubMed Web of Science ®Google Scholar
• Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14(12):1356–1364.
   PubMed Web of Science ®Google Scholar
• Yhim HY, Kim JS, Mun YC, et al. Consortium for Improving Survival of Lymphoma Study. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural Killer/T Cell lymphoma. Biol Blood Marrow Transplant. 2015;21(9):1597–1604.
   PubMed Web of Science ®Google Scholar
• Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant. 2009;44(11):709–714.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Anderson BO, Advani R, et al. Asian Oncology Summit. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1093–1101.
   PubMed Web of Science ®Google Scholar
• Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130(4):561–567.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2011;52(7):1255–1261.
   PubMed Web of Science ®Google Scholar
• Tse E, Chan TS, Koh LP, et al. Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant. 2014;49(7):902–906.
   PubMed Web of Science ®Google Scholar
• Kim WY, Nam SJ, Kim S, et al. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56(6):1778–1786.
   PubMed Web of Science ®Google Scholar
• Kim HK, Moon SM, Moon JH, et al. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015;50(40):254–256.
   PubMedGoogle Scholar
• Poon LM, Kwong YL. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Ann Hematol. 2016;95(5):847–849.
   PubMed Web of Science ®Google Scholar
• Huang Y, de Reyniès A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226–1237.
   PubMed Web of Science ®Google Scholar
• Chen BJ, B C, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–3473.
   PubMed Web of Science ®Google Scholar